ProVerum Appoints Ted Lamson as Special Advisor to Boost Innovative BPH Solutions ProVerum Limited has appointed Dr. Ted Lamson as Special Advisor, bringing over 30 years of medical device expertise to enhance BPH treatments.

ProVerum Appoints Ted Lamson as Special Advisor to Boost Innovative BPH Solutions #Ireland #Dublin #BPH_Treatment #ProVerum #Ted_Lamson

ProVerum Achieves Milestone with Successful Use of ProVee® System in U.S. for BPH Treatment ProVerum Limited celebrates the successful completion of its first commercial ProVee® System procedures in the U.S., marking a pivotal moment in BPH treatment.

ProVerum Achieves Milestone with Successful Use of ProVee® System in U.S. for BPH Treatment #United_States #Dublin #BPH_Treatment #ProVerum #ProVee_System

FDA Greenlights ProVee System: A Breakthrough for BPH Treatment ProVerum's ProVee System receives FDA approval as an innovative solution for benign prostatic hyperplasia, enhancing men's quality of life.

FDA Greenlights ProVee System: A Breakthrough for BPH Treatment #United_States #Dublin #BPH_Treatment #ProVerum #ProVee_System

ProVerum Raises $80 Million to Advance Breakthrough BPH Treatment ProVerum Limited has secured $80 million in Series B financing to advance the ProVee® System, a minimally invasive solution for BPH treatment. This funding will support the commercialization of their innovative technology.

ProVerum Raises $80 Million to Advance Breakthrough BPH Treatment #Ireland #Dublin #BPH_Treatment #ProVerum #ProVee_System

Resurge Therapeutics Reveals Promising Results for Innovative Prostate Treatment in Six-Month Study Resurge Therapeutics recently announced encouraging six-month clinical results for its innovative drug delivery therapy for prostate health, showing significant symptom relief.

Resurge Therapeutics Reveals Promising Results for Innovative Prostate Treatment in Six-Month Study #United_States #San_Jose #BPH_Treatment #Prostate_Therapy #Resurge_Therapeutics

Rivermark Medical Kicks Off RAPID III Study for Innovative BPH Treatment Rivermark Medical has successfully enrolled its first patient in the RAPID III clinical study, assessing the innovative FloStent™ system for BPH treatment.

Rivermark Medical Kicks Off RAPID III Study for Innovative BPH Treatment #United_States #Las_Vegas,_Nevada #BPH_Treatment #Rivermark_Medical #FloStent

Butterfly Medical to Showcase Innovative Device for BPH Treatment at AUA 2025 Butterfly Medical is set to present groundbreaking findings on its minimally invasive BPH treatment device at the upcoming AUA 2025 conference in Las Vegas, showing significant patient relief.

Butterfly Medical to Showcase Innovative Device for BPH Treatment at AUA 2025 #None #Las_Vegas #Minimally_Invasive #BPH_Treatment #Butterfly_Medical

Butterfly Medical Appoints Dr. James Ulchaker to Boost BPH Treatment Innovations Butterfly Medical has appointed Dr. James Ulchaker as Chief Medical Officer to enhance its treatment for Benign Prostatic Hyperplasia (BPH) and gain FDA approval.

Butterfly Medical Appoints Dr. James Ulchaker to Boost BPH Treatment Innovations #Israel #Yokneam #BPH_Treatment #Butterfly_Medical #Dr._Ulchaker

Benign Prostatic Hyperplasia Surgical Treatment Market Projected to Reach $17.19 Billion by 2030 The Benign Prostatic Hyperplasia surgical treatment market is anticipated to grow significantly, reaching $17.19 billion by 2030. A trend driven by an aging population and increasing obesity rates.

Benign Prostatic Hyperplasia Surgical Treatment Market Projected to Reach $17.19 Billion by 2030 #United_States #Delray_Beach #MarketsandMarkets #Benign_Prostatic_Hyperplasia #BPH_Treatment